EMV Capital advances XF-73 toward late-stage trials for surgical infection prevention

EMV Capital CEO Dr. Ilian Iliev and Executive Chairman Nigel Brooksby joined Steve Darling from Proactive to discuss the company’s progress in advancing XF-73, an antimicrobial drug candidate designed to help prevent surgical site infections. The program represents an important step in addressing a significant healthcare challenge, particularly as hospitals and healthcare systems continue searching for more effective approaches to reduce infection risks and improve patient outcomes. XF-73 is being developed as a first-in-class topical antimicrobial treatment intended to rapidly eliminate harmful bacteria before surgery. The therapy targets bacteria commonly found in the nasal cavity that can contribute to post-surgical infections and complications. Management highlighted that a previous Phase 2 clinical study demonstrated a 99.5% reduction in bacterial nasal carriage within just 24 hours among surgical patients, providing encouraging support for the treatment’s potential effective...